GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Jun 30, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Jun 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, transaction
TL;DR
GSK bought back some of its own stock in June 2025.
AI Summary
GSK plc announced on June 30, 2025, that it purchased a number of its own ordinary shares through its corporate stockbroker, Merrill Lynch International. The filing does not specify the exact number of shares or the total dollar amount involved in these transactions.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine report of share transactions and does not contain significant new financial or strategic information.
Key Players & Entities
- GSK plc (company) — The company making the share purchases.
- Merrill Lynch International (company) — The corporate stockbroker acting on behalf of GSK plc.
- June 2025 (date) — The period during which the share transactions occurred.
FAQ
What was the total number of GSK plc ordinary shares purchased in June 2025?
The filing states that GSK plc purchased a number of its ordinary shares but does not specify the exact quantity.
What was the total dollar amount spent on the share repurchases?
The filing does not disclose the total dollar amount spent on the share repurchases.
Who acted as GSK plc's corporate stockbroker for these transactions?
Merrill Lynch International acted as GSK plc's corporate stockbroker.
What is the par value of GSK plc's ordinary shares?
The ordinary shares of GSK plc have a par value of 31¼ pence each.
Is GSK plc required to file annual reports on Form 20-F or Form 40-F?
Yes, GSK plc indicates it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 30, 2025 regarding GSK plc (GLAXF).